Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, BioLine RX Ltd maintains a gross margin of 80.33%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -516.86%, while the net margin is -228.81%. These profitability ratios, combined with a Return on Equity (ROE) of -21.24%, provide a clear picture of how effectively BLRX converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, BLRX competes directly with industry leaders such as LTRN and OKUR. With a market capitalization of $13.40M, it holds a significant position in the sector. When comparing efficiency, BLRX's gross margin of 80.33% stands against LTRN's N/A and OKUR's N/A. Such benchmarking helps identify whether BioLine RX Ltd is trading at a premium or discount relative to its financial performance.
